购物车
- 全部删除
- 您的购物车当前为空
STAT3-IN-15是一款有效、具口服活性的STAT3抑制剂,用于对抗特发性肺纤维化(IPF)。该化合物阻止STAT3磷酸化,同时抑制TGF-β1引起的上皮细胞迁移及变形,并防止上皮间质转化(EMT)。
STAT3-IN-15是一款有效、具口服活性的STAT3抑制剂,用于对抗特发性肺纤维化(IPF)。该化合物阻止STAT3磷酸化,同时抑制TGF-β1引起的上皮细胞迁移及变形,并防止上皮间质转化(EMT)。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 10,500 | 6-8周 | |
50 mg | ¥ 13,700 | 6-8周 | |
100 mg | ¥ 17,400 | 6-8周 |
产品描述 | STAT3-IN-15, a potent and orally active inhibitor targeting STAT3, effectively combats idiopathic pulmonary fibrosis (IPF) by hindering STAT3 phosphorylation. Additionally, it impedes TGF-β1-induced migration and deformation of epithelial cells and prevents epithelial-mesenchymal transition (EMT), offering a multifaceted approach against IPF. |
分子量 | 422.42 |
分子式 | C20H17F3N2O3S |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容